Search

everythinglearnresearchcommunity

for

Search:↓

User shared successful hair regrowth results using Minoxidil and Microneedling with a Dr. Pen M8 model. Discussed routine, needle depth, and frequency for optimal results.

A user's 9-month progress using daily oral Fin/Min (1mg/2.5mg) for hair loss. The user experienced prolonged shedding but saw significant improvement by month 6, and took the medication in pill form as prescribed by their doctor.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

The user shared their 9-month hair regrowth progress using topical Minoxidil 5%, finasteride 0.05%, retinoic acid 0.01%, dermastamping, ketoconazole shampoo, and supplements like biotin. They experienced some hair density improvement but minimal change in the hairline, with initial side effects from finasteride that resolved after dosage adjustment.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

The conversation is about the effectiveness of using less than 20mg of RU58841, specifically 12.5mg, for hair loss treatment. People are discussing their experiences with different dosages of RU58841.

The user is updating on their 3-month progress using minoxidil (0.5mg twice daily) and microneedling once a week. They plan to consult a doctor about adding finasteride to their regimen.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.

The user plans to use an electric microneedling pen for hair loss, set to penetrate 0.6mm to 0.8mm, and apply rosemary oil in jojoba oil post-treatment. They also intend to use 5% Minoxidil daily, followed by a blend of rosemary, peppermint, and jojoba oils.

Hair loss treatment progress with Dut, Min, Keto, needling, and RU/Min/Fin/Dut topical. User noticed improvement, believes RU and needling most effective.

The user experienced significant hair regrowth using topical finasteride for 8-9 months, topical minoxidil for 3 months, and weekly microneedling with a stamp. They reported no side effects from the topical treatments and are considering a hair transplant for further improvement.

User had minor hair transplant in 2020, used Fin since 2008, Min since 2014, and added microneedling in 2022. Routine was irregular with no severe effects.

User experienced hair loss from Norwood 3.5 to Norwood 5 with diffuse thinning after using a hair system for 2 years. Tried Redensyl, Capixyl, Bicapil, Biotin, multivitamins, Fin, and Min without significant improvement, seeking advice for hair recovery.

A user expressed frustration with hair loss treatments, including finasteride, minoxidil with micro-needling, and RU58841, which all failed to stop hair thinning and miniaturization. Suggestions from others included accepting baldness, considering hair systems, and continuing prescribed antidepressants for depression.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.

A 33-year-old male has been using minoxidil, finasteride, and microneedling for hair loss since February 2024. Opinions vary, with some seeing no improvement and others noting stabilization.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

Finasteride has shown great results for hair loss. The discussion also inquires about the effectiveness and side effects of Low-Level Laser/Light Therapy (LLLT).

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

A user shared an 8-month hair regrowth progress using finasteride, topical minoxidil, and microneedling, and others reacted positively, asking for details about the treatment regimen. The user also mentioned taking cod liver oil and a hair multivitamin with biotin and collagen.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.